Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Insulet Corporation (NASDAQ:PODD) has received an average recommendation of “Moderate Buy” from the twenty-seven ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $252.0435.

Several analysts have recently commented on the company. Sanford C. Bernstein reduced their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. JPMorgan Chase & Co. reduced their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Jefferies Financial Group reduced their price target on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Barclays reduced their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Finally, Bank of America reduced their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th.

Insulet Trading Up 2.2%

Shares of PODD stock opened at $148.13 on Thursday. The business’s 50 day moving average is $181.94 and its two-hundred day moving average is $243.52. Insulet has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a market capitalization of $10.26 billion, a P/E ratio of 34.45, a price-to-earnings-growth ratio of 1.14 and a beta of 1.13. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period last year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts forecast that Insulet will post 6.44 EPS for the current year.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after purchasing an additional 87,845 shares during the last quarter. State Street Corp raised its holdings in Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after purchasing an additional 65,317 shares during the last quarter. Geode Capital Management LLC raised its holdings in Insulet by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares during the last quarter. Invesco Ltd. raised its holdings in Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after purchasing an additional 141,167 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.